News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Less Than Two Weeks Remain before Deadline in Class-Action Lawsuit Against Dendreon Corporation, Says Hagens Berman
September 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SEATTLE--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP reminds investors that those who wish to serve as lead plaintiff in a class-action lawsuit against Dendreon (NASDAQ:DNDN) have less than two weeks from today to file their motion.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Government
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts
June 30, 2025
·
2 min read
·
Tristan Manalac
Legal
Supreme Court Leaves PrEP Drug Coverage Decisions to RFK’s Task Force
June 27, 2025
·
2 min read
·
Annalee Armstrong
Vaccines
ACIP Skips Votes on COVID and Moderna’s mRESVIA but Scrutinzes mRNA Vaccine Safety
June 27, 2025
·
2 min read
·
Jef Akst
Government
Trump’s CDC Pick Says Vaccines Are Safe, Promises To Keep Them Available
June 26, 2025
·
2 min read
·
Tristan Manalac